Kindstar Globalgene Technology Inkomsten in het verleden
Verleden criteriumcontroles 1/6
Kindstar Globalgene Technology has been growing earnings at an average annual rate of 64.8%, while the Healthcare industry saw earnings growing at 11.2% annually. Revenues have been growing at an average rate of 2% per year. Kindstar Globalgene Technology's return on equity is 0.1%, and it has net margins of 1%.
Belangrijke informatie
64.8%
Groei van de winst
77.8%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 11.3% |
| Inkomstengroei | 2.0% |
| Rendement op eigen vermogen | 0.1% |
| Nettomarge | 1.0% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Kindstar Globalgene Technology's (HKG:9960) Shareholders Have More To Worry About Than Only Soft Earnings
Oct 04
We Think That There Are More Issues For Kindstar Globalgene Technology (HKG:9960) Than Just Sluggish Earnings
Apr 03Recent updates
Kindstar Globalgene Technology's (HKG:9960) Shareholders Have More To Worry About Than Only Soft Earnings
Oct 04Kindstar Globalgene Technology, Inc.'s (HKG:9960) Shares Leap 29% Yet They're Still Not Telling The Full Story
Oct 03We Think That There Are More Issues For Kindstar Globalgene Technology (HKG:9960) Than Just Sluggish Earnings
Apr 03Kindstar Globalgene Technology (HKG:9960) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Aug 22Analysts Just Made A Notable Upgrade To Their Kindstar Globalgene Technology, Inc. (HKG:9960) Forecasts
Aug 18We're Not Very Worried About Kindstar Globalgene Technology's (HKG:9960) Cash Burn Rate
Jul 07Kindstar Global (Beijing) Technology, Inc. (HKG:9960) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 28Opbrengsten en kosten
Hoe Kindstar Globalgene Technology geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 948 | 9 | 399 | 101 |
| 31 Mar 24 | 958 | 25 | 406 | 103 |
| 31 Dec 23 | 967 | 41 | 413 | 105 |
| 30 Sep 23 | 1,094 | 49 | 429 | 107 |
| 30 Jun 23 | 1,220 | 57 | 445 | 109 |
| 31 Mar 23 | 1,303 | 66 | 443 | 105 |
| 31 Dec 22 | 1,387 | 75 | 441 | 101 |
| 30 Sep 22 | 1,269 | 93 | 416 | 97 |
| 30 Jun 22 | 1,152 | 110 | 392 | 93 |
| 31 Mar 22 | 1,041 | -672 | 372 | 92 |
| 31 Dec 21 | 931 | -1,454 | 352 | 90 |
| 30 Sep 21 | 915 | -1,919 | 341 | 88 |
| 30 Jun 21 | 900 | -2,384 | 331 | 86 |
| 31 Mar 21 | 896 | -1,679 | 316 | 81 |
| 31 Dec 20 | 891 | -974 | 301 | 75 |
| 31 Dec 19 | 833 | -170 | 323 | 79 |
| 31 Dec 18 | 706 | -53 | 291 | 74 |
Kwaliteitswinsten: 9960 has a high level of non-cash earnings.
Groeiende winstmarge: 9960's current net profit margins (1%) are lower than last year (4.7%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 9960 has become profitable over the past 5 years, growing earnings by 64.8% per year.
Versnelling van de groei: 9960's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 9960 had negative earnings growth (-83.8%) over the past year, making it difficult to compare to the Healthcare industry average (-16.9%).
Rendement op eigen vermogen
Hoge ROE: 9960's Return on Equity (0.1%) is considered low.